Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31-year experience. [PDF]
Laryngoscope Investig Otolaryngol, 2022 Objective The purpose of this study was to quantitatively compare the effectiveness of unilateral and bilateral botulinum toxin A (BTX‐A) injections for mitigating undesirable weak/breathy voice quality and dysphagia for patients with adductor spasmodic ...
Stone A +7 more
europepmc +4 more sources
Post-treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo-controlled, randomized, double-blinded clinical trial in Japan. [PDF]
Laryngoscope Investig Otolaryngol, 2021 Objective Botulinum toxin (BT) therapy is a first‐line treatment for spasmodic dysphonia (SD). However, a detailed chronological course and clinical factors that affect the therapeutic effect have been vague.
Hirose K +7 more
europepmc +4 more sources
Machine Learning Assessment of Spasmodic Dysphonia Based on Acoustical and Perceptual Parameters. [PDF]
Bioengineering (Basel), 2023 Adductor spasmodic dysphonia is a type of adult-onset focal dystonia characterized by involuntary spasms of laryngeal muscles. This paper applied machine learning techniques for the severity assessment of spasmodic dysphonia.
Calà F +7 more
europepmc +2 more sources
Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update. [PDF]
Toxins (Basel), 2022 Spasmodic dysphonia (SD) is a rare neurological disorder that impairs phonatory function by triggering involuntary and intermittent contractions of the intrinsic laryngeal muscles. SD is classified into three types: adductor SD (AdSD), abductor SD (AbSD),
Hyodo M +4 more
europepmc +2 more sources
Laryngeal Imaging Study of Glottal Attack/Offset Time in Adductor Spasmodic Dysphonia during Connected Speech. [PDF]
Appl Sci (Basel), 2023 Adductor spasmodic dysphonia (AdSD) disrupts laryngeal muscle control during speech and, therefore, affects the onset and offset of phonation. In this study, the goal is to use laryngeal high-speed videoendoscopy (HSV) to measure the glottal attack time (
Naghibolhosseini M +4 more
europepmc +2 more sources
Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia. [PDF]
World J Otorhinolaryngol Head Neck Surg, 2023 Objectives This study aims to analyze the impact of age and sex on botulinum neurotoxin (BoNT‐A) dosing and outcomes in adductor spasmodic dysphonia (AdSD). Methods A database review of all spasmodic dysphonia patients treated with BoNT from 1989 to 2018
Heyes R +4 more
europepmc +2 more sources
Brainstem pathology in spasmodic dysphonia [PDF]
The Laryngoscope, 2009 AbstractSpasmodic dysphonia (SD) is a primary focal dystonia of unknown pathophysiology, characterized by involuntary spasms in the laryngeal muscles during speech production. We examined two rare cases of postmortem brainstem tissue from SD patients compared to four controls.
Kristina Simonyan +2 more
openaire +4 more sources
Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan. [PDF]
Toxins (Basel), 2021 Spasmodic dysphonia (SD) is a rare voice disorder caused by involuntary and intermittent spasms of the laryngeal muscles. Both diagnosis and treatment have been controversial.
Hyodo M +6 more
europepmc +2 more sources
Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study [PDF]
The Scientific World Journal, 2014 Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group) and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group)
Jae Wook Kim +3 more
doaj +2 more sources
Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. [PDF]
J Otolaryngol Head Neck Surg, 2020 Background Botulinum toxin A (BT) is the gold standard treatment for adductor spasmodic dysphonia (AdSD) with established use for greater than thirty years.
French G, Bosch JD, Randall DR.
europepmc +2 more sources